After 72 h of treatment, a significant dose‐dependent reduction in cell proliferation was observed in all ACC cell lines (MUC‐1: −91.1(15.3%), p < 0.001; NCI‐H295R: −51.8(28.5%), p < 0.01; TVBF‐7: −52.7(11.3%), p < 0.001 vs basal at 500 nM) (Figure 4C). Here, MUC1 is linked to adrenal cortex carcinoma.